---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-21-054869"
form_type: "8-K"
ticker: "SILO"
cik: "0001514183"
company_name: "Silo Pharma, Inc."
filed_at: "2021-10-27T23:59:59+00:00"
generated_at: "2026-06-28T17:26:18.378874+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "medium"
source: SEC EDGAR
---

# Silo Pharma partners with Columbia University on ketamine-based Alzheimer's therapeutic

## Summary
- Sponsored research agreement with Columbia University to develop ketamine treatment for Alzheimer's disease.
- Option to license novel inventions from Dr. Christine Ann Denny's lab targeting memory and cognitive aging.
- No financial terms or specific milestones disclosed in the agreement.
- Silo Pharma (OTCQB: SILO) is a development-stage biopharmaceutical company focused on psychedelics.

## SEC filing metadata
- accession: 0001213900-21-054869
- form_type: 8-K
- ticker: SILO
- cik: 0001514183
- company_name: Silo Pharma, Inc.
- filed_at: 2021-10-27T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: medium
- sec_items: 1.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1514183/000121390021054869/0001213900-21-054869-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1514183/000121390021054869/ea149452-8k_silopharma.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-21-054869
- JSON: https://secwatch.observer/filing/0001213900-21-054869.json
- Plain text: https://secwatch.observer/filing/0001213900-21-054869.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.